Addex Therapeutics (NASDAQ:ADXN) Shares Down 5.5% – Time to Sell?

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) dropped 5.5% during mid-day trading on Monday . The stock traded as low as $7.30 and last traded at $7.4250. Approximately 6,258 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 17,523 shares. The stock had previously closed at $7.86.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Addex Therapeutics has an average rating of “Sell”.

Addex Therapeutics Stock Performance

The company has a market capitalization of $7.87 million, a PE ratio of -1.26 and a beta of 1.37. The company’s 50-day simple moving average is $9.08 and its 200-day simple moving average is $8.66.

Addex Therapeutics (NASDAQ:ADXN) last announced its earnings results on Monday, September 29th. The company reported ($2.91) EPS for the quarter. Addex Therapeutics had a net margin of 3,584.49% and a negative return on equity of 68.40%.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.